Vascepa Gains European Filing Nod
No Rush In Search For Marketing Partner
On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement
You may also be interested in...
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.